BioAge Labs, Inc. (BIOA)

In August 2025, BioAge Labs announced its participation in investor conferences, leading to a mild positive market reaction. In September 2025, the company participated in investor conferences. In October 2025, Citi analyst Samantha Semenkow upgraded BioAge Labs (BIOA) to Buy and doubled the price target to $10, citing optimism regarding BGE-102. In December 2025, BioAge Labs participated in the Piper Sandler 37th Annual Healthcare Conference. In December 2024, the company announced the termination of its STRIDES trial for azelaprag, leading to a significant drop in stock price and a securities class action lawsuit. In January 2026, BioAge announced positive interim Phase 1 data for BGE-102 and a proposed public offering of common stock, followed by the pricing of an upsized $115.0 million public offering. Piper Sandler initiated coverage of BioAge Labs with an "overweight" recommendation. CEO Kristen Fortney sold shares under a pre-arranged trading plan. In February 2026, BioAge Labs' Chief Medical Officer, Paul D. Rubin, reported exercising stock options and selling shares. Wall Street Zen upgraded BioAge Labs to Hold. As of February 4, 2026, the share price of BioAge Labs, Inc. was $20.16, an increase of 3.28% from the prior week.

As a clinical-stage biopharmaceutical company, BioAge Labs, Inc. does not have commercialized products subject to traditional consumer demand seasonality. The demand for its pipeline products is driven by clinical trials, regulatory approvals, and market adoption. The company's revenue and expenses are primarily tied to research and development cycles, which are not typically seasonal.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases by targeting the biology of human aging. The company uses a proprietary platform integrating machine learning, omics data, and human biobanks to identify molecular drivers of aging and age-related diseases. Its product candidates include Azelaprag, which was terminated due to elevated liver enzymes; BGE-102, an NLRP3 inhibitor in Phase 1 trials for cardiovascular risk factors with plans for a Phase 1b/2a trial for diabetic macular edema; and APJ Agonists for obesity, with an IND submission anticipated by the end of 2026.

BioAge Labs, Inc. is headquartered in Richmond, California, United States. Its primary operational and research activities appear to be based in the U.S., with no explicit information found regarding significant international offices or market presence at this stage of development.

BioAge Labs' brand reputation has been impacted by both positive and negative developments. The termination of the Azelaprag STRIDES trial in December 2024 negatively impacted the reputation, leading to a stock price drop and a securities class action lawsuit. Positive developments include the announcement of positive interim Phase 1 data for BGE-102 in January 2026, analyst upgrades, and the successful pricing of an upsized public offering.

BioAge Labs, Inc. has significant institutional ownership, with 154 institutional owners holding 43% of the company. A total of 10 investors hold a majority stake with 52% ownership. Major institutional owners include AH Capital Management, L.L.C., Sofinnova Investments, Inc., Cormorant Asset Management, LP, ADAR1 Capital Management, LLC, Tang Capital Management Llc, Vanguard Group Inc, BlackRock, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Orbimed Advisors Llc, Sands Capital Ventures, LLC, and Andreessen Horowitz LLC. Private equity firms hold a 20% stake, and hedge funds own 11%. Key individual owners include Kristen Fortney, Dov Goldstein, and Paul Rubin. The general public holds approximately 19% ownership.